These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26869174)

  • 1. Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.
    Mao J; Tay S; Khojasteh CS; Chen Y; Hop CE; Kenny JR
    Pharm Res; 2016 May; 33(5):1204-19. PubMed ID: 26869174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
    Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
    Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
    Mao J; Johnson TR; Shen Z; Yamazaki S
    Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems.
    Albaugh DR; Fullenwider CL; Fisher MB; Hutzler JM
    Drug Metab Dispos; 2012 Jul; 40(7):1336-44. PubMed ID: 22490230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants.
    Eng H; Tseng E; Cerny MA; Goosen TC; Obach RS
    Drug Metab Dispos; 2020 Jun; 49(6):442-450. PubMed ID: 33811106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
    Xu L; Chen Y; Pan Y; Skiles GL; Shou M
    Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data.
    Rioux N; Batonga J; Colombo F; Massé J; Zouki C; Ribadeneira MD; Duan J; Bethell RC
    Xenobiotica; 2013 Jul; 43(7):592-7. PubMed ID: 23244592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions.
    Chen Y; Liu L; Monshouwer M; Fretland AJ
    Drug Metab Dispos; 2011 Nov; 39(11):2085-92. PubMed ID: 21835977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human.
    Haarhoff ZE; Kramer MA; Zvyaga TA; Zhang J; Bhutani P; Subramanian M; Rodrigues AD
    Xenobiotica; 2017 Jun; 47(6):470-478. PubMed ID: 27498589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model.
    Ramsden D; Perloff ES; Whitcher-Johnstone A; Ho T; Patel R; Kozminski KD; Fullenwider CL; Zhang JG
    Drug Metab Dispos; 2022 Feb; 50(2):114-127. PubMed ID: 34789487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.
    Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
    Drug Metab Dispos; 2012 Apr; 40(4):706-16. PubMed ID: 22228749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
    Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
    Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
    Polasek TM; Miners JO
    Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.
    Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
    Drug Metab Dispos; 2011 Apr; 39(4):591-602. PubMed ID: 21212240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
    Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
    Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.
    Zhao P; Lee CA; Kunze KL
    Drug Metab Dispos; 2007 May; 35(5):704-12. PubMed ID: 17293381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
    Zhang X; Galinsky RE; Kimura RE; Quinney SK; Jones DR; Hall SD
    Drug Metab Dispos; 2010 Jan; 38(1):61-72. PubMed ID: 19797607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes.
    Chapron B; Risler L; Phillips B; Collins C; Thummel K; Shen D
    J Pharm Pharm Sci; 2015; 18(1):101-11. PubMed ID: 25877445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
    Yadav J; Korzekwa K; Nagar S
    Mol Pharm; 2018 May; 15(5):1979-1995. PubMed ID: 29608318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.